RxDoctor Payments Data

Jaroslaw Sawka, DO

Family Medicine · Detroit, MINPI 1750373478

Payments from drug & device makers

$2,700in general payments, 2019–2025

Across 86 payments — averaging $31.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$713
  • AbbVie$554
  • Lilly USA, LLC$267
  • Exact Sciences$202
  • Abbott$169
  • Pfizer$164
  • plus $629 from 10 others

What the payments were for

  • Food & beverage$2,689100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,700 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$13,021
Medicare patients
39
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide62$60,771
OzempicSemaglutide46$43,039
EliquisApixaban27$14,716
JanuviaSitagliptin Phosphate17$11,754
FarxigaDapagliflozin Propanediol16$10,914
Arnuity ElliptaFluticasone Furoate40$10,487
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,633
JardianceEmpagliflozin13$7,278
Spiriva RespimatTiotropium Bromide13$6,981
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$6,553
Incruse ElliptaUmeclidinium Bromide19$6,454
Albuterol Sulfate HfaAlbuterol Sulfate152$4,113
Famotidine49$3,488
Ventolin HfaAlbuterol Sulfate60$3,160
Metformin Hcl133$2,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$267$60,77162 claims
Novo NordiskOzempic$116$43,03946 claims
PfizerEliquis$164$14,71627 claims
AstraZenecaFarxiga$713$10,91416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →